<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837391</url>
  </required_header>
  <id_info>
    <org_study_id>2019/1555</org_study_id>
    <nct_id>NCT04837391</nct_id>
  </id_info>
  <brief_title>Postoperative Cognitive Dysfunction in Elderly Urologic Oncology Patients (POCD)</brief_title>
  <acronym>POCD</acronym>
  <official_title>Evaluation of the Relationship Between Postoperative Cognitive Dysfunction and Brain Injury Biomarkers In Geriatric Urologic Oncology Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative cognitive changes are more common in elderly patients, which can result in poor&#xD;
      quality of life, loss of workforce, disability, early retirement, physical-social dependence,&#xD;
      increased health care cost and premature mortality. Postoperative cognitive complications are&#xD;
      also quite common in extensive oncological surgeries. In this study, our aim is to evaluate&#xD;
      the relationship between the development of postoperative cognitive dysfunction (POCD) in&#xD;
      geriatric urologic oncology patients with brain injury and inflammatory markers [S100 β,&#xD;
      neuron specific enolase (NSE), interleukin 6 (IL-6) and high mobility group box-1 (HMGB-1&#xD;
      protein)].&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of POCD changes by age group, type of surgery, testing neuropsychological&#xD;
      tests, timing of tests, and the method used for diagnosis. In non-cardiac surgery over the&#xD;
      age of 60; the incidence of POCD was 26% in the postoperative 1st week and 10% in the&#xD;
      postoperative 3rd month. Although old age is an important risk factor, POCD incidence of up&#xD;
      to 36.6% has been reported in a younger period. Major cancer surgery is an important risk&#xD;
      factor for development of POCD.&#xD;
&#xD;
      Numerous biomarkers such as; S100β, NSE, Human IL-6, HMGB-1 protein; have been evaluated in&#xD;
      studies to determine the diagnosis, prognosis, stage and treatment of POCD.&#xD;
&#xD;
      In this study, our aim is to evaluate the relationship between the development of&#xD;
      postoperative cognitive dysfunction (POCD) in geriatric urologic oncology patients with brain&#xD;
      injury and inflammatory markers. (S100β, NSE, Human IL-6 and HMGB-1 protein).The hypothesis&#xD;
      of our study is that postoperative brain injury and inflammatory markers (S100β, NSE, Human&#xD;
      IL-6 and HMGB-1 protein) will be higher in patients who develop POCD compared to patients who&#xD;
      do not develop POCD in geriatric urologic oncology surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2020</start_date>
  <completion_date type="Anticipated">July 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Addenbrooke cognitive examination at the day before surgery.</measure>
    <time_frame>The day before surgery.</time_frame>
    <description>Test score is between 0-100. 100 is the best point and 0 is the worst point in the test. The test has five cognitive domains including attention, memory, language, visuospatial function, and verbal fluency. Patients who score less than 88 in preoperative tests will be diagnosed with mild cognitive impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Addenbrooke cognitive examination at seventh day after surgery.</measure>
    <time_frame>The seventh day after surgery.</time_frame>
    <description>POCD is diagnosed by 1 standard deviation decrease from the preoperative test scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Addenbrooke cognitive examination at third months after surgery.</measure>
    <time_frame>The third months after surgery.</time_frame>
    <description>POCD is diagnosed by 1 standard deviation decrease from the preoperative test scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>S 100β (pg/mL)</measure>
    <time_frame>Change from baseline serum concentration of S 100 β at 6 hours</time_frame>
    <description>Blood S 100β concentration is determined by an enzyme-linked immunosorbent assay kit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Mobility Group Box1 Protein (HMGB1) (ng/mL)</measure>
    <time_frame>Change from baseline serum concentration of HMGB1 at 6 hours</time_frame>
    <description>HMGB1 concentration is determined by an enzyme-linked immunosorbent assay kit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Human Neuron Specific Enolase (h-NSE) (ng/mL)</measure>
    <time_frame>Change from baseline serum concentration of h-NSE at 6 hours</time_frame>
    <description>h-NSE concentration is determined by an enzyme-linked immunosorbent assay kit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukine-6 (IL-6) (pg/mL)</measure>
    <time_frame>Change from baseline serum concentration of IL-6 at 6 hours</time_frame>
    <description>Blood IL-6 concentration is determined by an enzyme-linked immunosorbent assay kit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative delirium</measure>
    <time_frame>Up to postoperative day one</time_frame>
    <description>Postoperative delirium is diagnosed by confusion assessment method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral oxygenation</measure>
    <time_frame>During surgery</time_frame>
    <description>Cerebral hypoxia is defined as reduction of regional oxygen saturation by 10 % from baseline before surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall postoperative complications</measure>
    <time_frame>Up to postoperative three months.</time_frame>
    <description>Stroke, transient ischemic attack, arrhythmia, heart failure, myocardial injury, respiratory failure, pneumonia, ileus, acute kidney injury, prolonged length of stay, mortality.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Postoperative Cognitive Dysfunction</condition>
  <condition>Postoperative Delirium</condition>
  <condition>Frailty</condition>
  <arm_group>
    <arm_group_label>Urologic oncology surgery in elderly</arm_group_label>
    <description>Elective urologic oncology surgeries such as radical nephrectomy, radical cystectomy, radical prostatectomy in older than 65 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Near Infrared Spectroscopy (NIRS)</intervention_name>
    <description>Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.</description>
    <arm_group_label>Urologic oncology surgery in elderly</arm_group_label>
    <other_name>INVOS Cerebral Oximeter 5100C (Covidien Dublin, Ireland)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.</description>
    <arm_group_label>Urologic oncology surgery in elderly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Addenbrooke Cognitive Examination III (ACE-III)</intervention_name>
    <description>ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.</description>
    <arm_group_label>Urologic oncology surgery in elderly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Confusion Assessment Method</intervention_name>
    <description>Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.</description>
    <arm_group_label>Urologic oncology surgery in elderly</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are collected from study participants after anesthesia induction and after the&#xD;
      end of the operation.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over the age of 65 who are planned to undergo major urooncological surgery&#xD;
        (radical nephrectomy, radical prostatectomy and radical cystectomy) as of April 21, 2020 at&#xD;
        the Istanbul University Hospital are included in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over the age of 65 who are planned to undergo major urooncological surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to participate in the study.&#xD;
&#xD;
          -  Patients with severe hearing-vision problems.&#xD;
&#xD;
          -  Patients with serious neurological-psychiatric disorders.&#xD;
&#xD;
          -  Patients with language barrier.&#xD;
&#xD;
          -  Patients with missing in any interventions.&#xD;
&#xD;
          -  Patients with blood samples that are not suitable for the ELISA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meltem Savran Karadeniz, Assoc. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emre Şentürk, MD</last_name>
    <phone>+905326114062</phone>
    <email>dr.emresentrk@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meltem Savran Karadeniz, Assoc.Prof.</last_name>
      <phone>+905334845563</phone>
      <email>mskaradeniz@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Yanagisawa R, Tanaka M, Yashima F, Arai T, Kohno T, Shimizu H, Fukuda K, Naganuma T, Mizutani K, Araki M, Tada N, Yamanaka F, Shirai S, Tabata M, Ueno H, Takagi K, Higashimori A, Watanabe Y, Yamamoto M, Hayashida K. Frequency and Consequences of Cognitive Impairmentin Patients Underwent Transcatheter Aortic Valve Implantation. Am J Cardiol. 2018 Sep 1;122(5):844-850. doi: 10.1016/j.amjcard.2018.05.026. Epub 2018 Jun 2.</citation>
    <PMID>30072128</PMID>
  </reference>
  <reference>
    <citation>Rundshagen I. Postoperative cognitive dysfunction. Dtsch Arztebl Int. 2014 Feb 21;111(8):119-25. doi: 10.3238/arztebl.2014.0119. Review.</citation>
    <PMID>24622758</PMID>
  </reference>
  <reference>
    <citation>Plas M, Rotteveel E, Izaks GJ, Spikman JM, van der Wal-Huisman H, van Etten B, Absalom AR, Mourits MJE, de Bock GH, van Leeuwen BL. Cognitive decline after major oncological surgery in the elderly. Eur J Cancer. 2017 Nov;86:394-402. doi: 10.1016/j.ejca.2017.09.024. Epub 2017 Nov 5.</citation>
    <PMID>29100194</PMID>
  </reference>
  <reference>
    <citation>Kapoor I, Prabhakar H, Mahajan C. Postoperative Cognitive Dysfunction. Indian J Crit Care Med. 2019 Jun;23(Suppl 2):S162-S164. doi: 10.5005/jp-journals-10071-23196. Review.</citation>
    <PMID>31485127</PMID>
  </reference>
  <reference>
    <citation>Androsova G, Krause R, Winterer G, Schneider R. Biomarkers of postoperative delirium and cognitive dysfunction. Front Aging Neurosci. 2015 Jun 9;7:112. doi: 10.3389/fnagi.2015.00112. eCollection 2015. Review.</citation>
    <PMID>26106326</PMID>
  </reference>
  <reference>
    <citation>Li RL, Zhang ZZ, Peng M, Wu Y, Zhang JJ, Wang CY, Wang YL. Postoperative impairment of cognitive function in old mice: a possible role for neuroinflammation mediated by HMGB1, S100B, and RAGE. J Surg Res. 2013 Dec;185(2):815-24. doi: 10.1016/j.jss.2013.06.043. Epub 2013 Jul 17.</citation>
    <PMID>23899512</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Meltem Savran Karadeniz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>postoperative cognitive dysfunction</keyword>
  <keyword>frailty</keyword>
  <keyword>S 100β</keyword>
  <keyword>NSE</keyword>
  <keyword>IL-6</keyword>
  <keyword>HMGB-1 protein</keyword>
  <keyword>NIRS</keyword>
  <keyword>geriatric anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Frailty</mesh_term>
    <mesh_term>Postoperative Cognitive Complications</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

